TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Artemisinin Resistance in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute symptomatic falciparum malaria infection as determined by malaria smear with a parasite density of 1,000 to 100,000 asexual parasites/uL as determined on the screening smear with fever (defined as ≥37.5C), or reported history of fever within the last 48 hours.~2. Age: 8-65 years old~3. All females between the age of 12 and 50 are required to have a negative human chorionic gonadotropin (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception throughout the study~4. Written informed consent obtained~5. Willing to stay under close medical supervision for the study duration of 42 days~6. Otherwise healthy outpatients~Exclusion Criteria:~1. Pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception~2. Mixed malaria infection on admission by malaria smear~3. A previous history of intolerance or hypersensitivity to the study drugs or to drugs with similar chemical structures~4. Malaria drug therapy administered in the past 30 days by history~5. History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk.~6. Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).~7. Signs or symptoms of severe malaria (as defined by WHO 2000)~8. Unable and/or unlikely to comprehend and/or follow the protocol

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AS 2mg/kg (Type: EXPERIMENTAL): Artesunate monotherapy 2mg/kg/day for 7 days
- AS 4mg/kg (Type: EXPERIMENTAL): Artesunate monotherapy 4mg/kg/day for 7 days
- QD Control (Type: ACTIVE_COMPARATOR): Quinine-doxycycline for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants with documented HIV infection with no detectable C-X-C Motif Chemokine Receptor 4 (CXCR4)~* Prior therapy for ≥3 months with ≥3 classes of currently marketed (US FDA-approved) antiretroviral agents (nucleoside reverse transcriptase inhibitor, NRTIs, non-nucleoside reverse transcriptase inhibitor (NNRTIs), protease inhibitor (PIs), or fusion inhibitors) at any time prior to screening~* HIV ribonucleic acid (RNA) ≥1000 copies/mL on a stable ART regimen for ≥6 weeks prior to Screening and ≥8 weeks prior to randomization~* ≥1 genotypically documented resistance mutation to a reverse transcriptase (RT) inhibitor and ≥1 primary resistance mutation to a PI~* Acceptable hematologic, renal and hepatic laboratory parameters~Exclusion Criteria:~* No history of previous malignancy (with the exceptions of cutaneous Kaposi's Sarcoma without visceral or mucosal involvement that resolved with highly active antiretroviral therapy (HAART) but without systemic anti-cancer treatment, and basal-cell carcinoma of skin surgically resected with disease-free margins on pathology exam)~* Treatment with cytotoxic cancer chemotherapy,~* Recurrent seizure, or central nervous system (CNS) condition or drug use predisposing to seizure in the opinion of the investigator~* No active acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind - Vicriviroc 30 mg (Type: EXPERIMENTAL): Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized antiretroviral therapy (ART) regimen containing a ritonavir-boosted protease inhibitor (PI/r) for 48 weeks.
- Double-Blind - Vicriviroc 20 mg (Type: EXPERIMENTAL): Vicriviroc 20 mg QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
- Double-Blind - Placebo (Type: PLACEBO_COMPARATOR): Placebo QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
- Open-label - Vicriviroc 30 mg (Type: EXPERIMENTAL): Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized ART regimen containing a ritonavir-boosted protease inhibitor (PI/r) for up to 45 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Uterine size no larger than 12 weeks LMP at time of presentation for care.~* Past or present history of vaginal bleeding during pregnancy.~* Open cervical os.~* If ultrasound used evidence of incomplete abortion with substantial debris in the uterus.~* All women would have been advised to have surgical evacuation of the uterus if misoprostol was not available.~* General good health.~* Willing to provide contact information for purposes of follow-up.~* Also in Egypt: 21 years of age or over or parental permission (there is no minimum age requirement in Niger, Mauritania and Senegal).~Exclusion Criteria:~* Contraindications to study drug~* Signs of severe infection, defined as at least one of the following: 1) foul smelling discharge, 2) fever \> 38 degrees C , 3) uterine tenderness~* Hemodynamic disturbances (pulse \>110/min and systolic bp \<100)~* Have an IUD in place; (the IUD may be removed making the woman eligible)~* Suspected ectopic pregnancy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- surgery (Type: ACTIVE_COMPARATOR): standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
- misoprostol (Type: ACTIVE_COMPARATOR): 400 mcg misoprostol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Upper-Extremity Motor Recovery in Post-stroke Hemiparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of cerebrovascular accident~* Single event~* Unilateral hemiplegia~* Between 6 months and 18 months post-event~* Impairment of upper-extremity function~* Ability to produce partial range of motion out of plane of gravity at shoulder, elbow, and wrist~* At least 10 degrees of wrist motion (any 10 degrees), and finger flexion/extension in 2 fingers~* Cognitive ability to follow 3-step commands~Exclusion Criteria:~* Unstable or uncontrolled blood pressure~* Uncontrolled seizures~* Flaccid hemiplegia~* Severe cognitive impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
- Experimental (Type: EXPERIMENTAL): POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of On-site CT-derived FFR in the Management of Suspect CAD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New-onset chest pain suspicious for CAD~* Coronary CTA result showed that the diameter stenosis is between 30 and 90% in at least one major coronary artery (coronary artery diameter ≥ 2.5 mm)~* Intermediate-to-high pretest probability of CAD based on CAD Consortium Score~* No prior evaluation for this episode of symptoms~* Agree to participate in this clinical study and sign written informed consent~Exclusion Criteria:~* Diagnosed or suspected acute coronary syndrome requiring hospitalization or emergent testing~* Hemodynamically or clinically unstable condition systolic blood pressure \< 90 mmHg or serious atrial or ventricular arrhythmias~* Known CAD with prior myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), or any angiographic evidence of ≥ 50% stenosis in any major coronary artery~* Patients with left main branch stenosis ≥ 50% or major coronary artery stenosis \> 90%~* Known severe congenital, valvular (moderate and above), or cardiomyopathy process (hypertrophic cardiomyopathy or reduced systolic left ventricular function ≤ 40%) which could explain cardiac symptoms~* Unable to provide written informed consent or participate in long-term follow-up.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CTA/CT-FFR care group (Type: EXPERIMENTAL): If the subjects are randomly allocated to CT-FFR arm, they will be examined by on-site DeepFFR for three major epicardial coronary arteries. If the result of CT-FFR calculation is less than or equal to 0.8 in one or more major coronary arteries, the patient will be referred to ICA directly; if the result of CT-FFR value is more than 0.8, optimal medical therapy will be recommended. The decision on the mode of revascularization is left to the treating cardiologists and depends on local practice standard.
- Routine clinically-indicated diagnostic care group (Type: NO_INTERVENTION): If the subjects are randomized to usual care arm, attending physicians will decide the next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, cardiac MR, and SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Green Tea Extract and Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* recent biopsy positive for prostate cancer~* scheduled for prostatectomy~* must be able to swallow capsules~* Palpable mass by digital rectal examination (DRE)~* Ability to give informed consent and willingness to adhere to study protocol~* Age ≥ 18 years and less than 75~Exclusion Criteria:~* abnormal liver function~* Prior hormonal or surgical therapy for prostate cancer~* Liver or kidney problems that would interfere with metabolism of study drug~* Any condition that would hamper informed consent or ability to comply with study protocol~* Participation in another research study in the last three months~* Known malignancy at any site other than prostate~* Recent consumption of green tea (5 or more cups per day, within one week prior to biopsy)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ECGC Extract (Type: EXPERIMENTAL): Single arm for a phase II study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Must have type 2 diabetes.~* Must be at least 30 and less than 80 years of age at the time of Visit 1.~* Must be on at least two oral antidiabetes medications for at least 90 days.~* Must have an HbA1c 1.2 to 2.0 times the upper limit of normal reference range at the local lab.~Exclusion Criteria:~* Must not have used insulin on a regular basis in the last 12 months.~* Must not have had more than one episode of severe hypoglycemia in the last 24 weeks.~* Must not have a body mass index (BMI) of greater than 45 (morbid obesity).~* Must not have clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease.~* Must not be pregnant or intend to get pregnant during course of the study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
- Lispro Low Mix (Type: EXPERIMENTAL): Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
- Lispro Mid Mix prior Lispro Low Mix addendum (Type: EXPERIMENTAL): Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
- Lispro Low Mix prior Glargine addendum (Type: EXPERIMENTAL): Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
- Basal bolus prior Lispro Low Mix addendum (Type: ACTIVE_COMPARATOR): Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
- Basal bolus prior Glargine addendum (Type: ACTIVE_COMPARATOR): Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types):~  1. Merkel Cell Carcinoma~ 2. Gastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type)~ 3. Nasopharyngeal Carcinoma~ 4. Squamous cell carcinoma (SCC) of the cervix, vagina, or vulva~ 5. Squamous cell carcinoma of the Head and Neck~ 6. Squamous cell carcinoma of the anal canal and penis~ 7. Recurrent/metastatic SCC of the cervix not amenable to curative treatment with surgery and/or radiation therapy who are unsuitable for platinum-based therapy may enroll in the cervical cancer Combination B expansion cohort~* Measurable disease by CT or MRI~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen)~* Men and women of age 18 or older~Exclusion Criteria:~* Active brain metastases or leptomeningeal metastases~* Patients with active, known or suspected autoimmune disease~* Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications~* Patients with hepatitis~* Patients with HIV~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified~\*\*Not participating: Japan, Korea, and Taiwan
- Metastatic Monotherapy Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified
- Nivolumab plus Ipilimumab Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~\*\*Not participating: Belgium, France and Germany~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico~\*\*Not participating in cohort expansion: France, Germany, Korea and Taiwan
- Nivolumab plus Relatlimab Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~\*\* Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort
- Nivolumab plus Daratumumab Cohort (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~\*\*Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent of parent(s) or legally acceptable representative of subject and child assent, as appropriate obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, ages 12 to below 18 years at the time of signing informed consent~* BMI equal to or above 95th percentile OR equal to or above 85th percentile (on gender and age-specific growth charts (CDC.gov)) with 1 or more weight related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes~* History of at least one self-reported unsuccessful dietary effort to lose weight~For subjects with type 2 diabetes at screening the following inclusion criteria apply in addition:~- HbA1c equal to or below 10.0% (86 mmol/mol) as measured by central laboratory at screening~Exclusion Criteria:~* Prepubertal subjects (Tanner stage 1)~* History of type 1 diabetes~* A self-reported (or by parent(s)/legally acceptable representative where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine causes)~* For subjects with type 2 diabetes only: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): 2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injected s.c. once weekly .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete